A supplier change notice can affect your product in ways that aren't obvious at first. This 60-minute webinar on impact assessments for supplier change notices presents strategies and tools for evaluating them thoroughly.
You'll learn how to decide whether a notice needs a full impact assessment and when lower-impact changes can be accepted or rejected without one. The session covers who should sit on the impact assessment team, which skill sets they need, how often to meet and how to evaluate notices, including verification and validation of the change.
It also highlights supplier and quality agreements with vendors, risk-based approaches to assessment, what happens if a change is unacceptable and how to set up incoming material specifications.
WHY SHOULD YOU ATTEND?
Pharmaceutical and medical device manufacturers are responsible for the quality and source of every incoming material. If a supplier change isn't evaluated properly, it can cause failed manufacturing runs or nonconforming product reaching the market, and FDA expects manufacturers to control incoming materials, so poor assessments can lead to enforcement action or recalls.
The session suits QA, regulatory affairs and supply chain professionals, technical scientists and production staff.
AREA COVERED
- Introduction to supplier change notices
- The regulatory impact of supplier change notices
- A risk-based approach to categorizing change notices
- Key skill sets for evaluating change notices and setting up a change impact team
- Verification and validation of supplier changes
- Key tools for impact assessments
- Supplier agreements and supplier or vendor quality agreements
- What happens if a change is unacceptable
- Setting up incoming material specifications
LEARNING OBJECTIVES
- Explain what supplier change notices are and why they matter to regulators
- Categorize change notices based on risk
- Set up a change impact team with the right skill sets
- Use supplier and quality agreements to require and manage change notices
- Respond when a supplier change is unacceptable
- Set up incoming material specifications
WHO WILL BENEFIT?
- QA professionals
- Technical scientists
- Production staff
- Regulatory Affairs professionals
- Supply chain professionals
Pharmaceutical and medical device manufacturers are responsible for the quality and source of every incoming material. If a supplier change isn't evaluated properly, it can cause failed manufacturing runs or nonconforming product reaching the market, and FDA expects manufacturers to control incoming materials, so poor assessments can lead to enforcement action or recalls.
The session suits QA, regulatory affairs and supply chain professionals, technical scientists and production staff.
- Introduction to supplier change notices
- The regulatory impact of supplier change notices
- A risk-based approach to categorizing change notices
- Key skill sets for evaluating change notices and setting up a change impact team
- Verification and validation of supplier changes
- Key tools for impact assessments
- Supplier agreements and supplier or vendor quality agreements
- What happens if a change is unacceptable
- Setting up incoming material specifications
- Explain what supplier change notices are and why they matter to regulators
- Categorize change notices based on risk
- Set up a change impact team with the right skill sets
- Use supplier and quality agreements to require and manage change notices
- Respond when a supplier change is unacceptable
- Set up incoming material specifications
- QA professionals
- Technical scientists
- Production staff
- Regulatory Affairs professionals
- Supply chain professionals
Speaker Profile
Alan M Golden
Alan M Golden has over 30 years of experience in the medical device industry, both in basic research and quality assurance. Alan spent 31 years at Abbott Laboratories. For the first 16 years as part of diagnostics R&D, he developed recombinant proteins used in diagnostics tests, received three US patents, and published numerous papers and abstracts. Alan then transitioned to a quality assurance role wherein both the Abbott Diagnostics and Abbott Molecular divisions, he was responsible for quality assurance for new product development, on-market product support, and operations.Alan’s quality assurance experience extends from design control, change control, risk …
Upcoming Webinars
Medical Device Cybersecurity Following FDA’s 2026 Premarket…
Managing Toxic Employees: Strategies For Leaders To Effecti…
California Meal and Rest Breaks: What You Don't Know Can Co…
Human Error Reduction Techniques for Floor Supervisors
Unlock Employee Loyalty: Stay Interviews Will Keep Them Eng…
Performance of Root Cause Analysis, CAPA, and Effectiveness…
Your AI Advantage: How HR Professionals Can Use Claude to S…
The Anti-Kickback Statute: Enforcement and Recent Updates
Empowering Conflict Resolution: Letting Go to Gain Control
Wage & Hour Laws: Ensuring Compliance with the Fair Labor S…
Using Copilot to Format Legal Documents in Microsoft Word
Dealing With Difficult People: At Work & In Life
Using Stay Interviews To Improve Employee Retention & Engag…
AI in Word - Smarter Writing and Document Creation with Cha…
FDA Current Trends in Compliance and Enforcement for FDA-Re…
Zero Acceptance Sampling to Reduce Inspection Costs
Why EBITDA Doesn't Spell Cash Flow and What Does?
Mastering Tough Conversations: Turn Conflict into Clarity, …
Enhancing Pivot Tables with Images: Visualize Your Data Lik…
Discover how Emotional Intelligence turns AI from a technic…
Understanding Financial Statements for Non-Financial Profes…
SOPs - How to Write Them to Satisfy those Inspectors
Managing Projects When AI Joins the Team: Human Judgment, A…